Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NB-VAL40
- Development stage
- Preclinical
- Lead developer
- Caleco Pharma
- Administration
- Oral
01
Overview
NB-VAL40 is a preclinical or early-stage investigational compound derived from natural products that Caleco Pharma has licensed from Natac Biotech for potential therapeutic development, most likely in the area of liver and metabolic diseases. Public disclosures identify NB-VAL40 only as one of five proprietary compounds covered by Caleco’s exclusive development and commercialization agreement, without specifying its precise chemical identity, modality, mechanism of action, or lead indication. Available information suggests it is part of a portfolio aimed at treating moderate to severe liver disorders, but no detailed pharmacology, clinical data, or regulatory status has been published.
Beyond the preview
Go deeper on NB-VAL40.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NB-VAL40.